Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
25 nov. 2016 07h45 HE
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
14 oct. 2016 09h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces Third Quarter 2016 Results
13 oct. 2016 23h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt
11 oct. 2016 16h46 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®
07 oct. 2016 18h35 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Responds to Recent Trading Activity
22 sept. 2016 16h05 HE
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
25 août 2016 16h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces Second Quarter 2016 Results
13 juil. 2016 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, July 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect
05 juil. 2016 07h30 HE
|
Intellipharmaceutics International Inc.
TORONTO, July 05, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Closes Public Offering for US$5.2 Million
06 juin 2016 17h30 HE
|
Intellipharmaceutics International Inc.
TORONTO, June 06, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of...